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This study investigated whether the mechanism of action of levetiracetam (LEV) is related to effects on neuronal voltage-gated
Na+ or T-type Ca2+ currents. Rat neocortical neurones in culture were subjected to the whole-cell mode of voltage clamping
under experimental conditions designed to study voltage-gated Na+ current. Additionally, visually identified pyramidal neu-
rones in the CA1 area of rat hippocampal slices were subjected to the whole-cell mode of voltage clamping under experimental
conditions designed to study low-voltage-gated (T-type) Ca2+ current. LEV (10 µM–1 mM) did not modify the Na+ current
amplitude and did not change (200 µM) the steady-state activation and inactivation, the time to peak, the fast kinetics of the
inactivation and the recovery from the steady-state inactivation of the Na+ current. Likewise, LEV (32–100 µM) did not modify
the amplitude and did not change the steady-state activation and inactivation, the time to peak, the fast kinetics of the inactiva-
tion and the recovery from the steady-state inactivation of the T-type Ca2+ current. In conclusion, neuronal voltage-gated Na+
channels do not appear directly involved in the antiepileptic mechanism of action of LEV, and LEV was devoid of effect on the
low-voltage-gated (T-type) Ca2+ current in hippocampal neurones.
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INTRODUCTION
Levetiracetam (LEV : (S)-α-ethyl-2-oxo-pyrrolidine
acetamide) is a new antiepileptic drug (AED) with
a unique pharmacological profile. LEV is devoid of
anticonvulsant activity in the two classical screen-
ing models for AEDs in mice and rats, the maximal
electroshock seizure test and the pentylenetetrazol
test1, 2. This contrasts potent seizure suppression, a
wide safety margin and antiepileptogenic properties in
kindling models of epilepsy2, 3. Clinical studies have
shown that LEV is effective as an add-on therapy in
the management of partial-onset seizures in adults4.
A specific binding site in rat brain has been described
for LEV5 and several studies have demonstrated an
ability to antagonize epileptiform responses in rat hip-
pocampal slices in vitro6, 7, but the mechanism(s) of
action of LEV remain to be characterized.
Inhibitory effects exerted on neuronal excitatory
voltage-gated currents, either Na+ currents or low-
voltage-activated (T-type) Ca2+ currents, are cel-
lular mechanisms which are commonly accepted
as accounting for the anti-seizure activities (e.g.
Reference 8) of several established and newer AEDs.
Several reference AEDs—chiefly phenytoin and car-
bamazepine, but also valproate9—as well as the
newer AEDs lamotrigine10 and topiramate11 have
been shown to reduce voltage-gated Na+ currents
in rat central neurones in culture. The established
AEDs ethosuximide, active against absence epilepsy,
and dimethadione, have been shown to reduce low-
voltage-activated (T-type) Ca2+ currents in rodent
thalamic neurones in vitro12.
The aim of the present study was to establish
whether the antiepileptic mechanism(s) of action of
LEV involve a modulation of Na+ or T-type Ca2+
channels in mammalian central neurones. Here we
report the results of whole-cell patch-clamp record-
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ings in vitro, investigating possible effects of LEV on
voltage-gated Na+ currents in rat cortical neurones
in culture and on low-voltage-activated (T-type) Ca2+
currents in the CA3 pyramidal neurones in rat hip-
pocampal slices. Some of these results have been com-
municated in abstract form13, 14.
MATERIALS AND METHODS
Na+ currents
Experiments were performed at room temperature on
neocortical neurones removed from 14 day old Wistar
rat embryos and grown in dissociated cell culture up
to 4 weeks in BME (Gibco) with the addition of 10%
foetal bovine serum (Gibco), 6 mM glucose, 2 mM
glutamine and 100 µg ml−1 of gentamicin (Gibco).
The results were obtained from 12 cortical culture
preparations.
Membrane currents were recorded from cell somas
of fusiform cells, with soma diameters of 20–26 µm,
in the whole-cell configuration of the patch-clamp
method. The resistance of the patch pipettes was
approximately 4 M. The currents were filtered at
3 KHz, digitized by computer at 10 KHz and stored
on a hard disc. Leakage currents were subtracted auto-
matically. Test pulses were usually applied at 3 second
intervals.
The standard saline bath solution (ACSF) con-
tained (in mM): NaCl, 120; KCl, 3; CaCl2, 2; MgCl2,
2; glucose 20; HEPES / NaOH, 10; pH 7.3. K+
and Ca2+currents were blocked by addition of 4-
aminopyridine (2 mM) and cadmium (200 µM), re-
spectively. The recording pipettes used for recording
sodium currents contained (in mM): CsCl, 130; TEA-
Cl, 20; MgCl2, 1; CaCl2, 0.24; EGTA, 5; ATP, 2; glu-
cose, 10; HEPES/CsOH, 10; pH 7.3. Neurones were
perfused with different concentrations of LEV, freshly
dissolved in the saline solution and applied by a grav-
ity perfusion system with small (diameter <1 mm)
tubes, placed at less than 0.2 cm from the patched cell.
During the experiments, the cells were continuously
superfused at a flow rate of 0.5–1 ml per minute.
Fitting with Boltzmann sigmoids the plots of the
mean normalized Na+ current amplitude (INa/I maxNa )
against either the step potential, or the holding po-
tential indicated the potentials V1/2, of either half-
activation, or half-inactivation, respectively. The rate
of Na+ current activation was expressed by the time to
peak (TTP), defined as the duration of the rising phase,
between the capacitive current and the peak of the Na+
current. TTP exponentially decays as a function of the
step voltage: TTP ∼ exp(−V/υact), with a voltage
constant υact. To characterize the rate of inactivation
of the Na+ currents—elicited from a holding potential
of −80 mV with step voltages increasing from −30 to
+30 mV—their fast falling phase was fitted with a sin-
gle exponential function of time (t):∼ exp(−t/τinact),
leading to the time constants τinact. The exponential
decay of τinact values as a function of the step volt-
age (V ): τinact ∼ exp(−V/υinact), indicates the volt-
age constant υinact. The rate of recovery from inacti-
vation of the Na+ currents, having an obvious impact
on repetitive neuronal firing, has also been assessed.
Na+ current was elicited in a two-pulse protocol, by
repeated depolarization from a holding potential of
−80 to −10 mV, with two 10 ms duration depolariz-
ing steps, separated by inter-pulse intervals (1t) rang-
ing from 0 to 30 ms. Since the Na+ current reached a
steady-state inactivation over the 10 ms duration of the
first depolarizing step, the second step elicited a Na+
current whose amplitude increased asymptotically as
a function of 1t : INa = I maxNa [1 − exp(−1t/τrec)],
with τrec representing the time constant of the recov-
ery from inactivation.
−10 mV
−80 mV
250 pA
2 ms
TTX 1 M
Fig. 1: Inward Na+ current, elicited from a holding potential
of −80 mV to a test potential of −10 mV, in a rat cortical
neurone, 8 days old in culture. The current was completely
blocked when the perfusion fluid contained 1 µM TTX (lower
trace).
Low-threshold Ca2+ currents
Whole-cell patch-clamp recordings were performed,
at about 28 ◦C, on pyramidal neurones in the CA1
area of hippocampal slices, visualized by near-infrared
differential interference contrast video microscopy.
The slices, 200 µm thick, were prepared from male
Sprague–Dawley rats weighing 20–50 g, according
to standard procedures, and were kept in oxygenated
ACSF containing (in mM): NaCl, 126; KCl, 3; CaCl2,
2.4; MgCl2, 1.3; NaH2PO4, 1.24; NaHCO3, 26; D-
glucose, 10; pH 7.4. Patch pipettes (with a resis-
tance of around 5 M) were filled with a solu-
tion containing (in mM): CsF, 110; NaCl, 15; CaCl2,
1; MgCl2, 2; TEA-Cl, 10; HEPES, 10; EGTA, 10;
Mg-ATP, 2; pH 7.2. To isolate the T-type current,
Na+ current and K+ currents were inhibited by ad-
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Fig. 2: Na+ currents elicited in rat cortical neurones in culture with step depolarizations from a holding potential of −80 mV to test
potentials increasing from −50 to +40 mV, in standard perfusion fluid (control, at left) and after 60 seconds perfusion with levetirac-
etam 200 µM (LEV, at right). The current–voltage curves show the Na+ current amplitude (given as mean ± SEM), normalized with
respect to its maximal value, as a function of the test potential (Vm) in a group of 18 cultured neurones, recorded in both control
saline and under LEV.
junction of tetrodotoxin (TTX; 0.75 µM in ACSF),
and Cs+ (5 mM in ACSF and 110 mM internally) plus
TEA (10 mM internally), respectively. High-threshold
Ca2+ currents were cancelled by their fast run-down.
Voltage-clamped recordings were collected with sam-
pling rates of either 0.625 or 1 KHz. The T-type cur-
rents, isolated as shown in Fig. 3, did not require any
further correction of leak conductance and capacitive
transients, but were corrected for the liquid junction
potential.
Upon entering into whole-cell configuration, the
zero time recording was taken only after com-
plete stabilization of the current, which usually took
20 minutes. After control recordings in normal ACSF,
the recordings were performed over 40 minutes perfu-
sion (flow rate 1 ml per minute) of the slices in LEV,
either 32 or 100 µM, freshly dissolved in ACSF, or
in ACSF alone. These (clinically relevant) concentra-
tions of LEV were used because previous studies have
shown that LEV exerts clear-cut in vitro effects in this
concentration range, between 10 and 100 µM6, 7.
The steady-state activation of the T-type current was
studied with voltage steps from −100 to −30 mV.
It was characterized by fitting the normalized ampli-
tude of the current with a rising Bolzmann sigmoid:
IT/I maxT = 1/{1 + exp[(V1/2 − V )/k]}, which gives
the half-activation potentials (V1/2) and the activa-
tion slopes (k). The steady-state inactivation was stud-
ied with 1 s conditioning steps increasing from −100
to −30 mV, followed by a step to −30 mV. It was
similarly analysed with a falling Bolzmann sigmoid:
IT/I maxT = 1/{1+exp[(V−V1/2)/k]}, which gives the
half-inactivation potentials (V1/2) and the slopes (k).
The rising (activation) and the falling (inactivation)
phases of the T-type current have been characterized
by the same parameters, as defined above for the Na+
current: the ‘time to peak’ (TTP) and the time constant
τinact. Also, the recovery from inactivation has been
described by the time constant τrec, as defined for the
Na+ current.
Statistics
The quantitative results are expressed as mean± SEM,
for the number of neurones recorded in each group.
The statistical significance of differences between ex-
perimental groups was assessed with Student’s t-test.
RESULTS
Na+ currents
When cortical neurones were voltage clamped at
−80 mV, a depolarization step to −10 mV elicited
an inward current that was completely blocked by
1 µM TTX in the external solution (Fig. 1). Extra-
cellular perfusion of different concentrations of LEV,
from 10 µM to 1 mM, for time intervals from 3 sec-
onds to 10 minutes, did not modify the amplitude of
this TTX-sensitive Na+ current (INa) in 25 neurones,
7–15 days old in culture. In view of the lack of effect
of LEV on Na+ current amplitude, a high concentra-
tion of 200 µM LEV was consistently used in further
investigations of the biophysical characteristics of the
Na+ current, in order to avoid overlooking an effect
of the drug which might only appear at the high limit
of clinically relevant concentrations. Indeed, a meta-
analysis on pharmacokinetic data from the four phase-
III studies performed so far with adjunctive therapy of
LEV in adults with refractory partial epilepsy reveals
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that clinically effective doses (1–3 g per day) result
in trough plasma levels between 35 and 100 µM and
C1hour (close to Cmax) levels between 90 and 250 µM
(unpublished results of UCB Pharma15).
In both control ACSF and that containing 200 µM
LEV, Na+ currents started to activate at a membrane
potential of −40 mV and peaked at −10 mV (Fig. 2).
Moreover, LEV did not change the steady-state acti-
vation of the Na+ currents, elicited from a holding
potential of −80 mV. The fit of the mean normalized
Na+ current amplitude against the step potential, indi-
cated similar half-activation potentials (V1/2) in both
control conditions and in the presence of LEV (Ta-
ble 1). In addition, LEV did not modify the steady-
state inactivation of the Na+ currents, elicited with
voltage steps applied every 5 seconds, from different
holding potentials to −10 mV. In both control ACSF
and that containing LEV, Na+ currents were simi-
larly reduced when the holding potential was more
positive than −90 mV and hardly any current could
be elicited from holding potentials more positive than
−40 mV. The fit of the normalized Na+ current ampli-
tude against the holding potential indicated quite sim-
ilar half-inactivation potentials (V1/2), in control con-
ditions and in the presence of LEV (Table 1).
Neither TTP values, nor their voltage constant υact,
have been influenced by the perfusion of LEV (Ta-
ble 2). Likewise, LEV did not influence either the τinact
values, or their voltage constant υinact, (Table 2). Also,
the recovery from inactivation of the Na+ currents, a
phenomenon having an obvious impact on the repet-
itive neuronal firing, was not influenced by LEV, as
shown by the time constant of the recovery from inac-
tivation (τrec), which was almost identical, irrespective
of the presence of LEV (Table 2).
Low-threshold Ca2+ currents
From a holding potential of−50 mV, voltage steps be-
tween −100 and −10 mV activate the low-threshold
(T-type) Ca2+ current in CA1 pyramidal neurones, to-
gether with the leak current and, possibly, a residual
Table 1: Voltages of half-activation and half-inactivation of
Na+ currents (V1/2), in rat cortical neurones, 7–21 days old
in culture, recorded in control perfusion fluid and under
60 seconds perfusion of levetiracetam 200 µM (LEV). V1/2,
arising from the fit with Boltzmann sigmoids of the voltage
dependencies of the normalized amplitudes of Na+ currents,
are given as mean ± SEM, for the number of neurones
indicated between parentheses.
V1/2(mV)
Control LEV
Activation (18) 30± 3.4 28.5± 4.6
Inactivation (13) −45.6± 2.7 −44.5± 2.5
−40 mV
−80 mV
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Fig. 3: Isolation of low-voltage gated (T-type) Ca2+ current
in a pyramidal CA1 neurone from a rat hippocampal slice.
From top, downward: activation of the T-type current to-
gether with the leak current and, possibly, a residual high-
threshold voltage-activated Ca2+ current, when the depolar-
ization steps from a holding potential of −50 mV are preceded
by a pre-step to −120 mV (upper), activation of only the leak
current and the residual high-threshold Ca2+ current, when
the depolarisation steps from the same holding potential are
preceded by a pre-step to −60 mV (middle) and the isolated
T-type currents, obtained by subtraction of the two families of
traces (lower). The inset shows the blocking of this current by
NiCl2 (200 µM).
high-threshold voltage-activated Ca2+ current, when
the steps are preceded by a 2 seconds pre-step to
−120 mV. However, when the steps are preceded
by a 2 seconds pre-step to −60 mV, only the leak
current and the residual high-threshold Ca2+ current
are activated. Accordingly, the T-type Ca2+ current is
isolated by subtraction of the two families of traces
(Fig. 3). This T-type Ca2+ current was blocked by
Ni2+ (200 µM; see the inset in Fig. 3) and by Co2+
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Table 2: Kinetic parameters of Na+ currents in rat cortical neurones, recorded in control perfusion fluid and under 60 seconds,
perfusion of levetiracetam 200 µM (LEV). TTP is the ‘time to peak’, defined in the text; τinact is the time constant of the
exponential decay of Na+ currents; υact and υinact are the voltage constants arising from exponential fits of the voltage
dependencies of TTP and τinact, respectively; τrec is the time constant of the recovery from inactivation, arising from the
exponential fit of the inter-pulse dependence of Na+ current amplitude (see Methods). All parameters are given as mean ± SEM,
for the number of neurones given between parentheses. No difference between control and LEV-treated groups is significant.
Activation (rising phase) Inactivation (falling phase) Recovery from
TTP (ms) υact τinact (ms) υinact inactivation
at −30 mV at −10 mV (mV) at −30 mV at +30 mV (mV) τrec (ms)
Control 2.47± 0.54 1.460± 0.021 14.6± 2.7 1.20± 0.20 0.300± 0.003 23.9± 2.5 3.5± 0.8
(9) (9) (9) (17) (17) (17) (8)
LEV 2.63± 0.42 1.470± 0.055 15.6± 1.8 1.20± 0.19 0.350± 0.005 22.5± 1.9 3.7± 0.7
(11) (11) (11) (21) (21) (21) (11)
Table 3: Voltages of half-activation and half-inactivation (V1/2) and slopes (k) of the voltage dependencies of the normalized
T-type current amplitudes, fitted with Boltzmann (rising for the activation, falling for the inactivation) sigmoids. The values are
mean ± SEM for groups of neurones recorded under perfusion with either control ACSF, or levetiracetam (LEV) 32 µM, or LEV
100 µM. The number of neurones in each group is given between parentheses. No difference between the groups is statistically
significant.
Activation Inactivation
V1/2 (mV) k (mV) V1/2 (mV) k (mV)
Time of recording
(min) 0 40 0 40 0 40 0 40
Control (6) −50.5± 2.5 −53.2± 2.6 2.6± 0.2 2.9± 0.5 −64.2± 2.1 −68.7± 1.6 −5.1± 0.3 −5.4± 0.1
LEV 32 µM (9) −49.3± 0.6 −51.5± 0.6 2.5± 0.3 3.2± 0.3 −64.2± 1.0 −68.1± 0.7 −5.1± 0.1 −5.3± 0.2
LEV 100 µM (7) −48.8± 1.1 −50.7± 1.3 3.1± 0.3 3.4± 0.3 −67.0± 1.0 −69.5± 0.1 −5.4± 0.3 −5.3± 0.7
(2.5 mM). However, LEV (32 µM, 100 µM) was
without effect on the amplitude of the T-type current
(Fig. 4).
The data in Table 3 show that neither the steady-
state activation, nor the steady-state inactivation of the
T-type current, characterized by the potentials of half-
effects (V1/2) and the slopes (k), were influenced by
LEV. Likewise, none of the kinetic parameters of the
T-type current in CA1 pyramidal neurones, the TTP
and the time constants τinact and τrec, were influenced
by LEV (Table 4).
DISCUSSION
This study revealed a complete lack of effect of LEV
on the neuronal (TTX-sensitive) Na+ current, studied
with the same methodology with which some of us
have previously shown clear-cut inhibitory effects of
both established9 and newer10, 11 AEDs, and of rilu-
zole16. This appears to corroborate pharmacological
observations with LEV in animal models of seizures
and epilepsy. LEV is distinct from Na+ channel block-
ers like phenytoin and carbamazepine by an absence
of anticonvulsant activity in the maximal electroshock
seizure test in mice and rats1, 2. In contrast, it has been
reported that LEV protects against seizures induced by
6 Hz electrical stimulation of mice via corneal elec-
trodes, which is a phenytoin-resistant seizure model17.
Furthermore, phenytoin, carbamazepine18 and, re-
cently, lamotrigine2 are known to be inactive against
focal seizures induced by systemic administration of
pilocarpine, while LEV affords potent protection in
this model2. Together with these results, the findings
of the present study suggest that the antiepileptic ac-
tion of LEV is unlikely to be mediated via inhibition
of neuronal Na+ channels.
In view of the commonly accepted association be-
tween absence epilepsy and the T-type Ca2+ cur-
rent (in thalamic neurones), one might have antici-
pated that LEV, which is active in several rat mod-
els of absence epilepsy, would reduce the T-type cur-
rent in hippocampal neurones, too. Specifically, LEV
suppresses spontaneous spike-and-wave discharges in
both GAERS rats19, and in rats administered a subcon-
vulsant dose of PTZ20. Also, the displacement of LEV
from its stereo-specific binding site in rat brain mem-
branes by the anti-absence drug ethosuximide at con-
centrations close to anti-convulsant plasma levels, re-
ported twice5, 21, and by the T-type current antagonist
amiloride21 would further favour a possible interaction
of LEV with the neuronal T-type current. In addition,
the antagonism by LEV of a non-GABAA receptor-
associated epileptiform effect of bicuculline in rat hip-
pocampus was mimicked by the non-specific calcium
antagonist flunarizine, known to preferentially block
the T-type current, while the prototypic L-type calcium
channel blocker nifedipine was without effect22.
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Table 4: Kinetic parameters of T-type current in pyramidal CA1 neurones of rat hippocampal slices, recorded over 40 minutes
perfusion in either control ACSF, or levetiracetam (LEV) 32 µM or LEV 100 µM. TTP is the ‘time to peak’, defined in the text; τinact
is the time constant of the exponential decay of T-type currents; τrec is the time constant of the recovery from inactivation, arising
from the exponential fit of the inter-pulse dependence of T-type current amplitude (see Materials and methods section). The
values are given as mean ± SEM, for the number of neurones indicated between parentheses. No difference between the groups
is significant.
Time of Activation Inactivation Recovery from
recording TTP (ms) τinact (ms) inactivation
(min) at −50 mV at −10 mV at −50 mV at −10 mV τrec (ms)
Control 0 37.3± 5.3 15.7± 1.0 29.7± 2.7 11.0± 1.3 424.8± 14.0
(6) (6) (6) (6) (6)
40 31.2± 3.0 14.1± 0.8 22.2± 2.0 11.4± 1.0 423.3± 31.6
(6) (6) (6) (6) (6)
LEV 32 µM 0 34.2± 4.0 14.1± 1.2 31.8± 5.8 11.2± 1.1 396.5± 15.0
(10) (10) (10) (10) (6)
40 32.5± 3.1 14.2± 1.2 26.2± 3.2 10.3± 1.0 424.4± 18.3
(10) (10) (10) (10) (6)
LEV 100 µM 0 33.4± 6.4 14.2± 1.4 22.6± 1.7 9.8± 1.1 436.2± 11.0
(8) (8) (8) (8) (6)
40 34.6± 6.7 14.2± 1.6 24.4± 2.3 9.9± 1.2 456.1± 12.0
(8) (8) (8) (8) (6)
In spite of all these indirect suggestions, the results
of the present study (Fig. 4 and Tables 3 and 4) dis-
miss any direct effect of LEV on the T-type current
in rat hippocampal neurones. Obviously, these results
cannot exclude, however, a putative effect of LEV on
the T-type current in thalamic neurones, on which the
activity of the ethosuximide was originally shown12.
However, our results support the view that an anti-
absence activity in vivo is not compulsorily associated
with an inhibition of the T-type Ca2+ current in all
rat brain neurones, since LEV, a drug active in rodent
models of absence-type seizures, did not affect the
T-type current in rat hippocampal neurones. In fact,
the anti-absence effects are in no way exclusive to T-
type Ca2+ channel blockers and the very hypothesis
that the therapeutic anti-absence action of ethosux-
imide arises from a reduction of the T-type current
was questioned23.
The current understanding of the antiepileptic mech-
anisms of LEV (whose antiepileptic properties have
been revealed by serendipitous screening) is only in-
cipient. The displacement of LEV from its specific
binding site in rat brain by the GABA-related con-
vulsants pentylenetetrazole and bemegride5 suggested
possible interactions between the LEV-binding site
and the GABAA complex. Subsequently, LEV was re-
ported to increase the activity of the GABA-degrading
enzyme GABA aminotransferase (GABA-T) in sev-
eral regions of the rat brain, including the striatum,
where it also decreased the activity of the GABA-
synthesizing enzyme glutamic acid decarboxylase
(GAD)24. A reduced GABAergic activity in the stria-
tum is known to be anticonvulsant25, since a disin-
hibited striatal output enhances the inhibition in the
substantia nigra pars reticulata, a brain region which
receives a strong GABAergic input from the striatum
and controls seizure propagation26. Since Lo¨scher et
al.24 recorded, indeed, a decreased spontaneous fir-
ing of (presumably) GABAergic neurons in the sub-
stantia nigra pars reticulata following LEV, these au-
thors hypothesized that it might contribute to the an-
ticonvulsant action of the drug. However, a wealth of
data, starting with the absence of any affinity of LEV
for the GABA receptors5, prevent ascribing to LEV
any conventional GABAergic facilitation. Indeed, the
fact that LEV induced (only at the relatively high dose
170 mg kg−1 i.p.) in regions of rat brain both increases
and decreases in GABA-T and GAD activities, while
not altering the activities of these enzymes in vitro,
led Lo¨scher et al.24 to conclude that the enzyme al-
terations they found were but indirect consequences
of post-synaptic changes. Moreover, GABA turnover
was normalized 60 minutes after LEV, casting seri-
ous doubts on the anticonvulsant relevance for the
antiepileptic action of LEV of the alterations in GABA
turnover, since the time of the peak effect of LEV was
previously reported to be 60 minutes in both mice and
rats1. Furthermore, LEV (up to 300 mg kg−1 i.p.; sin-
gle/multiple doses) had no effect on the concentrations
of GABA, glutamate and glutamine, and on the activi-
ties of GAD and GABA-T in mice brains27. Also, LEV
had no effect on GABA transport and metabolism in
rat astrocyte culture28. Accordingly, it was concluded
that it is unlikely that the action of LEV would be me-
diated via the GABAergic system27, 28.
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Fig. 4: Lack of effect of LEV on the amplitude of the low-
voltage gated (T-type) Ca2+ currents in pyramidal CA1 neu-
rones from rat hippocampal slices, elicited and isolated as de-
scribed in Fig. 3. The graphs represent (mean ± SEM) the
current–voltage dependencies before and after 40 minutes
perfusion of either ACSF (upper graph, for n = 6 neurones),
or LEV 32 µM (middle graph, for n = 10 neurones), or LEV
100 µM (lower graph, for n = 8 neurones). No statistically
significant difference was found between the three groups of
neurones.
While these studies, along with our results presented
above, disclaim for LEV any conventional mechanism
currently accepted for the established AEDs, very re-
cent data suggest that LEV might control pathologic
neuronal excitability via multiple modulatory actions.
To date, these include an inhibition of high-voltage-
activated Ca2+currents in pyramidal neurons from rat
hippocampal slices29 and a suppression of the in-
hibitory effects of several negative allosteric modula-
tors, including the Zn2+ions and β-carbolines, on both
GABA-gated currents in cultured rat hippocampal and
cerebellar granule neurons and glycine-gated currents
in spinal neurons30. Furthermore, an inhibition of the
AMPA-gated current in cultured rat hippocampal neu-
rons has also been reported, but only at relatively high
concentrations31. Obviously, it is too early to conclude
on the anti-seizure relevance of these effects and there
is little doubt that further cellular effects of LEV might
be unraveled in the forthcoming years.
CONCLUSION
This study reveals the absence of effect of LEV
on neuronal voltage-activated Na+ current and low-
voltage-activated Ca2+ current, i.e. on two major
mechanisms accepted for established AEDs. Along
with previous reports, this suggests that LEV exerts its
antiepileptic action via non-conventional mechanisms,
the exact nature of which can only be identified by fu-
ture studies. Beyond its mechanistic interest, the out-
come of this study is of potential relevance for orient-
ing antiepileptic polytherapy.
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